The present in vivo study extends these findings, by showing that acute D1R-induced PKA and ERK1/2 activation are downregulated by repeated l-DOPA treatment, suggesting that while D1R signalling may be reduced by chronic l-DOPA treatment, the D1R-driven dyskinesia nevertheless increases. Here, MAPK3 is linked to drug-induced dyskinesia.